免疫检查点抑制剂毒性预测生物标志物的研究进展  

Research progress of predictive biomarkers for immune-related adverse events

作　　者：邓俊[1] 王均[1] 高嫦娥[1] 陈晓[1] 史明霞[1] DENG Jun;WANG Jun;GAO Chang′e;CHEN Xiao;SHI Mingxia(the First Affiliated Hospital of Kunming Medical colledge,Kunming 650000,China)

机构地区：[1]昆明医科大学第一附属医院,昆明650000

出　　处：《实用医学杂志》2023年第20期2561-2565,共5页The Journal of Practical Medicine

基　　金：国家自然科学基金资助项目(编号:82160547);云南省科技厅-昆明医科大学应用基础研究联合专项资金资助项目(编号:202201AC070524)。

摘　　要：在癌症免疫治疗时代,随着越来越多的临床试验结果公布,免疫检查点抑制剂(ICIs)的适应证也越来越广泛,然而大约40%的患者会经历免疫相关不良事件(irAEs),甚至部分患者出现致命性的irAEs,早期识别irAEs可降低irAEs相关死亡及医疗花费,而生物标志物是早期识别ICIs所致毒性反应的重要指标。本文旨在回顾irAEs预测生物标志物的最新进展,通过其梳理指导进行更方便、快捷的预测因子或预测模型的研究,最终服务于临床工作。In the era of cancer immunotherapy,with the release of more clinical trial results,the use of ICIs is more and more widely,but about 40% of these patients will experience irAEs,even some patients with fatal irAEs,early identification of irAEs can reduce irAEs related deaths and medical costs,and biomarkers are an important indicator of early identification of toxic reaction caused by ICIs.We review the latest progress in predicting biomarkers of irAEs,guiding the study of more convenient and fast predictors or predictive models through the combing of biomarkers,ultimately serving clinical work.

关 键 词：免疫检查点抑制剂 免疫相关不良事件 预测生物标志物 

分 类 号：R730.5[医药卫生—肿瘤]